Astellas Pharma has acquired the U.K.-based gene therapy company Quethera, which is developing novel treatment for ocular disorders, Astellas announced in a press release.
The transaction includes Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system to introduce therapeutic genes into target retinal cells to treat glaucoma, the release said.
“This acquisition demonstrates Astellas’ commitment to proactively incorporate state-of-the-art scientific and technological advances and turn them into value for patients,” Kenji
Uncategorized